- Home
- CMDB vs OABI Comparison
CMDB vs OABI Comparison
Compare CMDB & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMDB
- OABI
- Stock Information
- Founded
- CMDB 2023
- OABI 2012
- Country
- CMDB Monaco
- OABI United States
- Employees
- CMDB N/A
- OABI N/A
- Industry
- CMDB
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- CMDB
- OABI Health Care
- Exchange
- CMDB Nasdaq
- OABI Nasdaq
- Market Cap
- CMDB 209.8M
- OABI 236.1M
- IPO Year
- CMDB N/A
- OABI N/A
- Fundamental
- Price
- CMDB $9.10
- OABI $1.98
- Analyst Decision
- CMDB
- OABI Strong Buy
- Analyst Count
- CMDB 0
- OABI 3
- Target Price
- CMDB N/A
- OABI $7.00
- AVG Volume (30 Days)
- CMDB 109.1K
- OABI 644.3K
- Earning Date
- CMDB 08-12-2025
- OABI 08-07-2025
- Dividend Yield
- CMDB N/A
- OABI N/A
- EPS Growth
- CMDB N/A
- OABI N/A
- EPS
- CMDB N/A
- OABI N/A
- Revenue
- CMDB $1,195,401,000.00
- OABI $26,744,000.00
- Revenue This Year
- CMDB N/A
- OABI N/A
- Revenue Next Year
- CMDB N/A
- OABI $45.02
- P/E Ratio
- CMDB N/A
- OABI N/A
- Revenue Growth
- CMDB 80.27
- OABI 27.07
- 52 Week Low
- CMDB $8.46
- OABI $1.22
- 52 Week High
- CMDB $11.99
- OABI $4.96
- Technical
- Relative Strength Index (RSI)
- CMDB N/A
- OABI 63.68
- Support Level
- CMDB N/A
- OABI $1.93
- Resistance Level
- CMDB N/A
- OABI $2.11
- Average True Range (ATR)
- CMDB 0.00
- OABI 0.13
- MACD
- CMDB 0.00
- OABI 0.02
- Stochastic Oscillator
- CMDB 0.00
- OABI 62.69
About CMDB Costamare Bulkers Holdings Limited Common Stock
Costamare Bulkers Holdings Ltd is an international owner and operator of dry bulk vessels providing multinational transportation of dry bulk commodities for a broad range of customers. Its owned fleet consists of 38 vessels, with a total carrying capacity of approximately 3,017,000 dwt. The company's vessels transport a broad range of major and minor bulks across global shipping routes. Iron ore, coal and grain constitute the majority of its cargoes.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.